SI
SHOULDER INNOVATIONS, INC.
Medical - Specialties
Market Cap$265M
5Y Perf.-3.1%
Compare Stocks
2 / 10Try these comparisons:
Stock Comparison
SI vs XTNT
Revenue, margins, valuation, and 5-year total return — side by side.
XTNT
Xtant Medical Holdings, Inc.
Medical - Devices
Market Cap$81M
5Y Perf.-19.4%
SI vs XTNT — Key Financials
Market cap, revenue, margins, and valuation side-by-side.
| Company Snapshot | SI | XTNT |
|---|---|---|
| Industry | Medical - Specialties | Medical - Devices |
| Market Cap | $265M | $81M |
| Revenue (TTM) | $32M | $133M |
| Net Income (TTM) | $-16M | $2M |
| Gross Margin | 77.0% | 62.0% |
| Operating Margin | -46.3% | 4.8% |
| Total Debt | $15M | $35M |
| Cash & Equiv. | $6M | $6M |
Quick Verdict: SI vs XTNT
Each card shows where this stock fits in a portfolio — not just who wins on paper.
Bottom line: XTNT leads in 4 of 6 categories, making it the strongest pick for profitability and margin quality and capital preservation and lower volatility. SHOULDER INNOVATIONS, INC. is the stronger pick specifically for growth and revenue expansion. As sector peers, any of these can serve as alternatives in the same allocation.
SI
SHOULDER INNOVATIONS, INC.
The Growth Play
SI is the clearest fit if your priority is growth exposure and long-term compounding.
- Rev growth 64.1%, EPS growth -22.2%
- -14.4% 10Y total return vs XTNT's -97.6%
- 64.1% revenue growth vs XTNT's 28.4%
Best for: growth exposure and long-term compounding
XTNT
Xtant Medical Holdings, Inc.
The Income Pick
XTNT carries the broadest edge in this set and is the clearest fit for income & stability and sleep-well-at-night.
- beta 0.69
- Lower volatility, beta 0.69, Low D/E 81.8%, current ratio 2.35x
- Beta 0.69, current ratio 2.35x
Best for: income & stability and sleep-well-at-night
See the full category breakdown
| Category | Winner | Why |
|---|---|---|
| Growth | SI | 64.1% revenue growth vs XTNT's 28.4% |
| Quality / Margins | XTNT | 1.3% margin vs SI's -49.4% |
| Stability / Safety | XTNT | Beta 0.69 vs SI's 0.76 |
| Dividends | Tie | Neither stock pays a meaningful dividend |
| Momentum (1Y) | XTNT | +13.5% vs SI's -14.4% |
| Efficiency (ROA) | XTNT | 1.8% ROA vs SI's -32.1% |
SI vs XTNT — Revenue Breakdown by Segment
How each company's revenue is distributed across its business units
Segment breakdown not available.
FY 2024
SI vs XTNT — Financial Metrics
Side-by-side numbers across 2 stocks — who leads on profitability, valuation, growth, and risk.
BEST OVERALLXTNTLAGGINGSI
SISHOULDER INNOVATIONS,…
0leads
XTNTXtant Medical Holding…
1leads
6 Total Categories
CATEGORYLEADERvs SIMETRICS WON
Income & Cash FlowRevenue, margins, and cash flow strength
XTNT3/4
Valuation MetricsMultiples, price ratios, and targets
Tied
—
Profitability & EfficiencyROE, ROIC, leverage, and quality scores
Tied
—
Total Returns1Y, 3Y, 5Y total returns with dividends
Tied
—
Risk & VolatilityBeta, volatility, and downside exposure
Tied
—
Analyst OutlookRatings, price targets, and dividends
—
—
Income & Cash Flow (Last 12 Months)
XTNT leads this category, winning 3 of 4 comparable metrics.
Income & Cash Flow (Last 12 Months)
XTNT is the larger business by revenue, generating $133M annually — 4.2x SI's $32M. XTNT is the more profitable business, keeping 1.3% of every revenue dollar as net income compared to SI's -49.4%.
| Metric | SISHOULDER INNOVATI… | XTNTXtant Medical Hol… |
|---|---|---|
| RevenueTrailing 12 months | $32M | $133M |
| EBITDAEarnings before interest/tax | — | $11M |
| Net IncomeAfter-tax profit | — | $2M |
| Free Cash FlowCash after capex | — | $5M |
| Gross MarginGross profit ÷ Revenue | +77.0% | +62.0% |
| Operating MarginEBIT ÷ Revenue | -46.3% | +4.8% |
| Net MarginNet income ÷ Revenue | -49.4% | +1.3% |
| FCF MarginFCF ÷ Revenue | -57.4% | +3.9% |
| Rev. Growth (YoY)Latest quarter vs prior year | — | +19.0% |
| EPS Growth (YoY)Latest quarter vs prior year | — | +123.7% |
XTNT leads this category, winning 3 of 4 comparable metrics.
Valuation Metrics
Evenly matched — SI and XTNT each lead in 1 of 2 comparable metrics.
Valuation Metrics
| Metric | SISHOULDER INNOVATI… | XTNTXtant Medical Hol… |
|---|---|---|
| Market CapShares × price | $265M | $81M |
| Enterprise ValueMkt cap + debt − cash | $274M | $110M |
| Trailing P/EPrice ÷ TTM EPS | -16.74x | -4.81x |
| Forward P/EPrice ÷ next-FY EPS est. | — | — |
| PEG RatioP/E ÷ EPS growth rate | — | — |
| EV / EBITDAEnterprise value multiple | — | — |
| Price / SalesMarket cap ÷ Revenue | 8.39x | 0.69x |
| Price / BookPrice ÷ Book value/share | — | 1.80x |
| Price / FCFMarket cap ÷ FCF | — | — |
Evenly matched — SI and XTNT each lead in 1 of 2 comparable metrics.
Profitability & Efficiency
Evenly matched — SI and XTNT each lead in 3 of 6 comparable metrics.
Profitability & Efficiency
On the Piotroski fundamental quality scale (0–9), SI scores 3/9 vs XTNT's 2/9, reflecting mixed financial health.
| Metric | SISHOULDER INNOVATI… | XTNTXtant Medical Hol… |
|---|---|---|
| ROE (TTM)Return on equity | — | +3.8% |
| ROA (TTM)Return on assets | -32.1% | +1.8% |
| ROICReturn on invested capital | — | -12.8% |
| ROCEReturn on capital employed | -34.3% | -17.9% |
| Piotroski ScoreFundamental quality 0–9 | 3 | 2 |
| Debt / EquityFinancial leverage | — | 0.82x |
| Net DebtTotal debt minus cash | $9M | $29M |
| Cash & Equiv.Liquid assets | $6M | $6M |
| Total DebtShort + long-term debt | $15M | $35M |
| Interest CoverageEBIT ÷ Interest expense | -11.13x | 1.55x |
Evenly matched — SI and XTNT each lead in 3 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
Evenly matched — SI and XTNT each lead in 3 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
A $10,000 investment in SI five years ago would be worth $8,565 today (with dividends reinvested), compared to $3,395 for XTNT. Over the past 12 months, XTNT leads with a +13.5% total return vs SI's -14.4%. The 3-year compound annual growth rate (CAGR) favors XTNT at -3.9% vs SI's -5.0% — a key indicator of consistent wealth creation.
| Metric | SISHOULDER INNOVATI… | XTNTXtant Medical Hol… |
|---|---|---|
| YTD ReturnYear-to-date | -10.3% | -23.1% |
| 1-Year ReturnPast 12 months | -14.4% | +13.5% |
| 3-Year ReturnCumulative with dividends | -14.4% | -11.2% |
| 5-Year ReturnCumulative with dividends | -14.4% | -66.1% |
| 10-Year ReturnCumulative with dividends | -14.4% | -97.6% |
| CAGR (3Y)Annualised 3-year return | -5.0% | -3.9% |
Evenly matched — SI and XTNT each lead in 3 of 6 comparable metrics.
Risk & Volatility
Evenly matched — SI and XTNT each lead in 1 of 2 comparable metrics.
Risk & Volatility
XTNT is the less volatile stock with a 0.69 beta — it tends to amplify market swings less than SI's 0.76 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. SI currently trades 71.9% from its 52-week high vs XTNT's 60.7% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | SISHOULDER INNOVATI… | XTNTXtant Medical Hol… |
|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 0.76x | 0.69x |
| 52-Week HighHighest price in past year | $17.94 | $0.95 |
| 52-Week LowLowest price in past year | $10.92 | $0.44 |
| % of 52W HighCurrent price vs 52-week peak | +71.9% | +60.7% |
| RSI (14)Momentum oscillator 0–100 | 42.4 | 61.8 |
| Avg Volume (50D)Average daily shares traded | 86K | 143K |
Evenly matched — SI and XTNT each lead in 1 of 2 comparable metrics.
Analyst Outlook
Insufficient data to determine a leader in this category.
Analyst Outlook
| Metric | SISHOULDER INNOVATI… | XTNTXtant Medical Hol… |
|---|---|---|
| Analyst RatingConsensus buy/hold/sell | Buy | — |
| Price TargetConsensus 12-month target | $23.00 | — |
| # AnalystsCovering analysts | 3 | — |
| Dividend YieldAnnual dividend ÷ price | — | — |
| Dividend StreakConsecutive years of raises | — | — |
| Dividend / ShareAnnual DPS | — | — |
| Buyback YieldShare repurchases ÷ mkt cap | 0.0% | 0.0% |
Insufficient data to determine a leader in this category.
Key Takeaway
XTNT leads in 1 of 6 categories — strongest in Income & Cash Flow. 4 categories are tied.
Best OverallXtant Medical Holdings, Inc. (XTNT)Leads 1 of 6 categories
Loading custom metrics...
SI vs XTNT: Frequently Asked Questions
8 questions · data-driven answers · updated daily
01Is SI or XTNT a better buy right now?
For growth investors, SHOULDER INNOVATIONS, INC.
(SI) is the stronger pick with 64. 1% revenue growth year-over-year, versus 28. 4% for Xtant Medical Holdings, Inc. (XTNT). Analysts rate SHOULDER INNOVATIONS, INC. (SI) a "Buy" — based on 3 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which is the better long-term investment — SI or XTNT?
Over the past 5 years, SHOULDER INNOVATIONS, INC.
(SI) delivered a total return of -14. 4%, compared to -66. 1% for Xtant Medical Holdings, Inc. (XTNT). Over 10 years, the gap is even starker: SI returned -14. 4% versus XTNT's -97. 6%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
03Which is safer — SI or XTNT?
By beta (market sensitivity over 5 years), Xtant Medical Holdings, Inc.
(XTNT) is the lower-risk stock at 0. 69β versus SHOULDER INNOVATIONS, INC. 's 0. 76β — meaning SI is approximately 11% more volatile than XTNT relative to the S&P 500.
04Which is growing faster — SI or XTNT?
By revenue growth (latest reported year), SHOULDER INNOVATIONS, INC.
(SI) is pulling ahead at 64. 1% versus 28. 4% for Xtant Medical Holdings, Inc. (XTNT). Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.
05Which has better profit margins — SI or XTNT?
Xtant Medical Holdings, Inc.
(XTNT) is the more profitable company, earning -14. 0% net margin versus -49. 4% for SHOULDER INNOVATIONS, INC. — meaning it keeps -14. 0% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: XTNT leads at -10. 3% versus -46. 3% for SI. At the gross margin level — before operating expenses — SI leads at 77. 0%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
06Which pays a better dividend — SI or XTNT?
None of the stocks in this comparison currently pay a material dividend.
All are effectively zero-yield and should be held for capital appreciation rather than income.
07Is SI or XTNT better for a retirement portfolio?
For long-horizon retirement investors, Xtant Medical Holdings, Inc.
(XTNT) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 69)). Both have compounded well over 10 years (XTNT: -97. 6%, SI: -14. 4%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
08What are the main differences between SI and XTNT?
Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.
These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform both.
Revenue Growth>
%
(SI: 64.1% · XTNT: 19.0%)You Might Also Compare
Based on how these companies actually compete and overlap — not just which sector they're filed under.